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Tricarboxylic acid cycleThe prevalence of obesity among children, adolescents and adults has been dramatically increasing
worldwide during the last several decades. The obesity epidemic has been recognized as one of the major
global health problems, because its health hazard is linked to a number of common diseases including breast
and prostate cancers. Obesity is caused by combination of genetic and environmental factors. While genetic
contribution to obesity has been known to be signiﬁcant, the genetic factors remain relatively unchanged.
Recent studies have highlighted the involvement of environmental “obesogens”, i.e. the xenobiotic chemicals
that can disrupt the normal development and homeostatic control over adipogenesis and energy balance.
Several lines of evidence suggest that increasing exposure to chemicals with endocrine-disrupting activities
(endocrine-disrupting chemicals, EDCs) contributes to the increased obesity. The cellular and molecular
mechanisms underlying obesogen-associated obesity are just now being appreciated. In this paper, we
comprehensively reviewed current knowledge about the role of estrogen receptors alpha and beta (ERα and
ERβ) in regulation of energy metabolism pathways, including glucose transport, glycolysis, tricarboxylic acid
(TCA) cycle, mitochondrial respiratory chain (MRC), adenosine nucleotide translocator (ANT) and fatty acid
β-oxidation and synthesis, by estrogens; and then examined the disturbance of E2/ER-mediated energy
metabolism pathways by environmental obesogens; and ﬁnally, we discussed the potential implications of
disturbance of energy metabolism pathways by obesogens in obesity and pointed out several key aspects of
this area that need to be further explored. A better understanding of the cellular and molecular mechanisms
underlying obesogen-associated obesity will lead to new approaches for slow down and/or prevention of the
increased trend of obesity associated with exposure to obesogens.© 2009 Elsevier B.V. All rights reserved.1. IntroductionThe prevalence of obesity (deﬁned as excessive body fat withmore
than 25% of body fat in men andmore than 30% of body fat inwomen)
among children, adolescents and adults has been dramatically
increasing during the last several decades [1–3]. Worldwide, more
than one billion adults are overweight and over 300 million are obese
[4]. The majority of developed countries particularly The United States
[5] and England [6] and the rapidly developing countries such as China
[7] and India [8] have been experiencing dramatic increases in obesity.
The obesity epidemic has been recognized as one of the major global
health problems, because its health hazard is linked to several types of
common diseases including type 2 diabetes, heart disease, high blood
pressure, stroke, pulmonary problem, liver disease, psychological/
social problems, and reproductive problems [4,9], as well as withll rights reserved.breast [9,10] and prostate [11] cancers. Thus, great efforts must be
made to prevent and/or slow down this trend.
Obesity is caused by combination of genetic and environmental
factors. While genetic contribution to obesity has been known to be
signiﬁcant, the genetic factors remain relatively unchanged [12]. Thus,
the current epidemic of obesity and associated metabolic diseases
could be attributed to the dramatic changes in the environmental and
nutritional factors over the last several decades [3,14,15]. The
increased caloric intake and decreased physical activities are thought
to be one of themajor causes of this dramatic increase. However, there
are several lines of evidence that highlight the potential involvement
of environmental “obesogens”, i.e. the xenobiotic chemicals that can
disrupt the normal development and homeostatic control over
adipogenesis and energy balance [16,17]. Increasing exposure to the
industrial and agricultural chemicals with endocrine-disrupting
activities (endocrine-disrupting chemicals, EDCs) released into the
environment could be another factor contributing to the increased
obesity [3,13,14]. In order to prevent the increased trend of obesity
related to exposure to obesogens (e.g. EDCs), it is important to
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obesogen-associated obesity. In this review, we ﬁrstly gleaned several
lines of evidence indicating the role of estrogen receptors alpha and
beta (ERα and ERβ) in regulation of energy metabolism pathways by
estrogens; Secondly, we examined the disturbance of E2/ER-mediated
energy metabolism pathways by environmental obesogens; Finally,
we discussed the potential implications of disturbance of energy
metabolism pathways by obesogens in relation to obesity that may be
causally related to exposure to environmental obesogens.
2. Role of estrogens, estrogenic chemicals and ERs in obesity
2.1. Involvement of estrogens, estrogenic chemicals in regulation of body
weight and obesity
There is accumulating evidence indicating that endogenous
estrogens, e.g. 17β-estradiol (E2), and environmental estrogenic
EDCs are involved in the regulation of body weight and obesity. For
instance, it has been observed that treatment of Syrian hamsters with
estrogens caused signiﬁcant decreases in body weight and fat content
without affecting food intake [15]. Deﬁciency or loss of estrogens in
adult animals, e.g. in follicle-stimulating hormone receptor knock out
mice [20], ovariectatomied (Ovx) mice and Syrian hamster [21–24],
and aromatase knock out (ARKO) mice [16–18], is associated with
bodyweight gain and the development of obesity. Furthermore, more
interestingly, Gao et al. [19] reported that estrogens regulated the
body weight and energy metabolism in the brain in a way similar to
that of the leptin, the hormone that regulates energy metabolism in
the brain. During menopause women tend to gain body fat. The
increase in adiposity is likely due to the decline in endogenous
estrogens [20]. On the other hand, estrogen therapy has positive
effects on carbohydrate and lipid metabolism in overweight-obese
younger postmenopausal women [21,22].
2.2. Role of ERα and ERβ in E2 regulation of body weight and obesity
The biological effects of estrogens are mainly mediated via
estrogen ERs, i.e. ERα and ERβ, by regulating the expression of
estrogen-responsive genes via nuclear ERs [23–27] and by eliciting
several rapid, non-nuclear genomic signaling pathways via the plasma
membrane-associated ERs [28–32]. Mitochondria are also important
targets for the action of estrogens and ERs [33,34]. Several lines of
evidence have pointed to the involvement of ERα and ERβ in
mediating estrogen's effects on body weight. First, tamoxifen (TAM),
an anti-estrogen, signiﬁcantly attenuated the effects of E2 on reducing
body weight when given concurrently with E2 [15]. Second, ICI
182,780, another pure estrogen antagonist, has been shown to
antagonize the effects of E2 on estrous behavior and energy balance
in Syrian hamsters [35]. Third, the role of ERα in E2 regulation of body
weight and obesity is supported by following observations: a) both
male and female mice that have been genetically altered to reduce the
ability to produce estrogen by knocking out aromatase (ARKO), an
enzyme that catalyzes the conversion of androgen to estrogen,
became obese when fed the same amounts as normal mice [36,37];
b) Increased white adipose tissue (WAT) and body fat were seen in
both sexual mature male and female ERα knocked out (ERαKO) mice
[38,39]. ERα absence caused adipocyte hyperplasia/hypertrophy,
insulin resistance, and glucose intolerance and reduced energy
expenditure in both sexes, clearly indicating that E2/ERα signaling is
critical in female and male WAT and that obesity in ERαKO mice
involves a mechanism of reduced energy expenditure [39,40].
The role of ERβ in E2 regulation of body weight and obesity is less
clear and somewhat controversial. Unlike ERαKO mice, ERβKO mice
did not show a clear increase in total body fat and enhanced serum
leptin levels [38,40]. Because ERαKO mice undergo a 10-fold increase
in E2, a persistent or even increased E2 signaling through ERβ could bea factor in obesity of ERαKO mice. A study by Naaz et al. [41] has
revealed a role of ERβ in adipose tissue. These investigators
ovariectomized (Ovx) or sham-ovariectomized (sham-Ovx) adult
female ERαKO mice and then treated them with vehicle or E2, and
measured bodyweights and food consumption at 28 days after
treatment. They observed that sham-Ovx ERαKO mice had increase
in bodyweight whereas Ovx ERαKO mice showed a 6 % decrease, and
E2 replacement restored body weight to sham levels. Fat pads of Ovx
ERαKO mice showed 45% and 16% decreases in bodyweight and
adipocyte circumference, respectively, compared to sham-Ovx or E2-
replaced Ovx ERαKO mice. Ovx ERαKO mice showed a trend towards
decreased feed consumption that did not reach signiﬁcance. Blood
glucose levels were lower both before and after glucose injection in
Ovx mice compared to sham ERαKO mice, and E2 treatment reversed
this. Insulin levels following glucose challengewere lower in Ovxmice
compared to sham-Ovx ERαKO mice, indicating that ovariectomy
ameliorated the glucose intolerance and insulin resistance in ERαKO
mice. Immunohistochemical analysis revealed strong staining for ERβ
in adipose tissue. These observations indicate that removing E2/ERβ
signaling in ERαKO mice by ovariectomy decreases body and fat-pad
weights and adipocyte size, while improving insulin and glucose
metabolism. Thus, ERβmediated effects on adipose tissue are opposite
those of ERα, although E2 effects on adipose tissue are predominately
through ERα. Another study by Foryst-Ludwig et al. [42] revealed that
ERβ inhibited ligand-mediated transcriptional activity induced by
proxisomal proliferator activating receptor-gamma (PPAR-γ), a
master regulator of insulin signaling/glucose metabolism, resulting
in a blockade of PPAR-γ-induced adipocytic gene expression and
decreased adipogenesis. Several types of mutations in human ERβ
gene have been identiﬁed in some obese adolescents andwomenwith
bulimic disease [43,44]. Liang et al. [45] observed that Ovx in 8-week
old female Wistar rats induced hyperphagia in association with
increased bodyweight and abdominal fat accumulation. These effects
were fully reversed by subcutaneous E2 replacement. These investi-
gators examined the effects of intracerebroventricular infusion of E2,
alone or in combination with anti-sense oligonucleotides for either
ERα or ERβ in Ovx rats. The E2-treated group showed a 10–20% lower
daily food intake after the 2-week infusion period, and a 14% reduction
in body weight with similar reduction in abdominal fat compared to
the control group. The inhibitory effects of E2 on food intake and
bodyweight were blocked by co-administration of anti-sense oligo-
nucleotides of ERβ but not of those of ERα. These observations suggest
that ERβ is involved in the anorectic action of estrogen and in the
modulation of bodyweight. It has been shown that the ratio of ERα to
ERβ in adipose tissue was associated with obesity as well as the serum
level and production of leptin in omental adipose tissue [46]. Together,
these observations indicate that regulation of bodyweight and obesity
by estrogens and estrogenic chemicals are differentially mediated via
ERα and ERβ.
As mentioned above, both ERα and ERβ are localized in nucleus,
plasmamembrane andmitochondria. While the relative contributions
of these different pools of ERs to estrogen regulation of body weight
and obesity have yet clearly addressed, a recent study by Pedram et al.
[47] indicated that expression of ERα functional domain in plasma
membrane in ERαKOmice did not rescue these mice from developing
obesity. These investigators generated a transgenic mouse expressing
only a functional E domain of ERα at the plasma membrane (MOER).
These MOER female mice exhibited comparable activation of ERK and
phosphatidylinositol 3-kinase, which was not seen in cells from
ERαKO mice, indicating that several membrane ERα-mediated
signaling pathways were retained in these mice. However, ovaries of
MOER, like those in homozygous Strasbourg ERαKO mice, showed
multiple hemorrhagic cysts and no corpus luteum. Their mammary
gland development was also rudimentary. More importantly, MOER
mice showed plentiful abdominal visceral and other depots of fat and
increased body weight compared to wild-type mice despite
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ERα is likely not involved in E2 regulation of body weight and obesity.
As described below, the nuclear andmitochondrial ERs are involved in
the regulation of proteins/enzymes involved in several energy
metabolism pathways, it is likely that the nuclear and mitochondrial
pools of ERαmay be responsible for E2 regulation of body weight and
obesity.
3. Imbalance of energy metabolism/utilization and obesity
Obesity is associated with the accumulation of excessive body fat
resulting from chronic imbalance of energy whereby the intake of
energy exceeds expenditure. A balanced body energy budget
controlled by limitation of calorie uptake and/or increment of energy
expenditure is the most effective way against obesity. An elevation of
energy expenditure and/or a suppression of energy intake are the
ways to reduce obesity.
The energy metabolism pathways in the cells include: a) glucose
transport, b) glycolysis; c) tricarboxylic acid (TCA) cycle, d) mito-
chondrial respiratory chain (MRC) mediated electron transfer/
oxidative phosphorylation; and e) ATP translocation and utilization.
The biochemical pathways involved in energy storage include fatty
acid (FA) biosynthesis/oxidation and triglyceride biosynthesis/dis-
position. A well balance of energy ﬂow requires the coordination of
these biochemical pathways involved in the entire energymetabolism
pathways. Overabundance in some pathways coupled with the
deﬁciency in other pathways will cause energy imbalance. Metabolic
energy expenditure ﬂow (glucose transport→glycolysis→TCA
cycle→MRC→ATP utilization) negatively regulates energy balance,
whereas energy storage processes (FA biosynthesis→FA disposi-
tion→cholesterol and triglycerides synthesis/storage) and storage of
low-density lipoproteins could opposite the energy balance. Catabolic
pathways split carbohydrate molecules into small molecules and
generate reduced coenzymes (NADH and FADH) and ATP. For
example, it has been shown [48] that enhancing hepatic glycolysis
by over-expressing the key enzymes involved in glycolysis, e.g.
glucokinase and 6-phospho fructose-2-kinase/fructose-2,6-bispho-
sphatase, reduced bodyweight and adiposity in obese mice. On the
other hand, inhibition and/or deﬁciency in other links of the energy
expenditure ﬂow chain may lead to abnormal energy ﬂow. Chronic
physical, biochemical and cellular activities that disturb the energy
balance could either reduce or enhance obesity.
4. Regulation of energy metabolism pathways and energy
utilization by estrogens and ERs and their disturbance of by
endocrine-disrupting chemicals
It has been observed that during pregnancy or after experimental
manipulations of ovarian hormones (e.g. Ovx and replacement
therapy with E2 or with E2+progesterone), Syrian hamsters exhibited
changes in energy balance and body fat content without modifying
their food intake, suggesting that estrogens play an important role in
the regulation of energy balance [49]. In fact, estrogens and ERs are
involved in the regulation of energy metabolism and utilization from
glucose transport→glycolysis/glucoegenesis→TCA cycle→MRC-
mediated electron transport/oxidative phosphorylation→ATP trans-
location (ANT) and utilization by directly or indirectly regulating the
activity and expression of the key enzymes/proteins involved in these
processes (Fig. 1).
A large number of exogenous chemicals are capable of altering
endocrine functions and causing adverse effects at the levels of
organism, its progeny and/or subpopulation of organisms. Some of
which posses estrogenic and/or anti-estrogenic activities and are
capable of disrupting endocrine systems and thus, are deﬁned as
endocrine-disrupting chemicals (EDCs) [50]. It has been reported [51]
that exposure of animals to several EDCs, including phytoestrogens,synthetic estrogens (e.g. diethylstilbestrol, DES) and environmental
EDCs caused changes in bodyweight and development of obesity: i)
developmental exposure to low dose of DES is associated with
decreased body weight gain, in association with signiﬁcantly elevated
metabolic rate [52,53]; ii) Neonatal exposure to soybean products
enriched in phytoestrogens altered body weight, adiposity and
adipokines in adult female mice, indicating that brief exposure to
phytoestrogens early in life affect mouse white adipose mass and
serum adenosines [54,55]; and iii) A signiﬁcant decrease in maternal
body weight gain and food consumption was seen in pregnant rats
treated with butyl benzyl phthalate (BBP) by gastric incubation at
1000 mg/kg on days 15 to 17 of pregnancy. This treatment also caused
signiﬁcant decreases in the weighs of their male and female fetuses
[56]. It has been reported [57] that the offspring of Sprague–Dawley
female rats exposed prerinatally to low doses (0.1 mg/kg body
weight/day) of bisphenol A (BPA), a monomer used in the
manufacture of polycarbonate plastics and resins, from day 6 of
pregnancy through the period of lactation, exhibited an increased
body weight that was apparent soon after birth and continued into
adulthood. The female offspring from female rats exposed perinatally
to high dose (1.2 mg/kg body weigh/day) to BPA exhibited altered
patterns of estrous cycle and decreasing levels of plasma luteinizing
hormone in adulthood. Decreasedmaternal body weight, bodyweight
gain and reduced food consumption in pregnant rats and their fetuses
was also observed in pregnant female rats exposed perinatally to BPA
[58,59]. There is increasing concern for the adverse health outcomes
after developmental exposure to these environmental EDCs capable of
perturbing the endocrine systems. The known adverse effects caused
by exposure to these EDCs include the low reproductive activity in
female offspring and high increase of reproductive tract dysfunction in
both male and female offsprings. Another important consequence of
exposure of animals to these EDCs is the altered body weight (either
gain or loss). However, the cellular and molecular mechanisms by
which E2 and EDCs are involved in the regulation of body weight and
obesity are poorly understood, pointing to the urgent need of a
comprehensive investigation into this area. As described below, EDCs
are capable of disturbing several key aspects of E2/ER-mediated
energy metabolism pathways.
4.1. Regulation of glucose transport by E2/ERs and potential disturbance
by EDCs
4.1.1. Regulation of glucose transport by E2/ERs
Hexoses including glucose and fructose play an essential role in
energy metabolism and other cellular metabolism. Glucose enters
eukaryotic cells via so-called “glucose transporters”, the membrane-
associated carrier proteins. There are two different types of glucose
transporters: the Na+-coupled glucose transporters (SGLT) and
glucose transporter facilitators (GLUT). SGLT family consists of three
members: SGLT1, SGLT2 and SGLT3. SGLT1 and SGLT2 function as
sugar transporters whereas SGLT-3 serves as a glucose sensor. Human
GLUT family consists of 14 members (designated GLUT-1 to GLUT-14),
among which eleven are involved in sugar transport. The individual
isoforms of glucose transporters exhibit different substrate speciﬁcity,
kinetic characteristics, and expression proﬁles, thereby allowing a
tissue-speciﬁc adaptation of glucose uptake through regulation of
their gene expression. In addition, some transporters (e. g. GLUT-4 and
GLUT-8) are regulated by their subcellular distribution. In addition to
mediating glucose entry into cells, some isoforms (e.g., GLUT-2)
appear to be responsible for glucose sensing of pancreatic β-cells,
neuronal, or other cells, thereby playing a major role in the hormonal
and neural control (for review see [60]). More importantly, several
congenital defects of sugar metabolism are associated with aberrant
transporter genes. For instance, aberrant SGLT1 is related to the
glucose-galactose malabsorption syndrome whereas deﬁciency in
GLUT-1 is related to the glucose transporter 1 deﬁciency syndrome.
Fig. 1. Proposed models for the regulation of energy metabolism pathways and utilization by estrogens and ERs. There could be two energy ﬂows: constitutive energy ﬂow, indicated
by the black arrows; and E2/ER-indcued energy ﬂow, indicated by the bold red arrows.
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tion of glucose transporter expression or regulation of GLUT-4 appears
to be related the insulin resistance syndrome [60]. Increased uptake
of glucose compared to cells in normal tissue is a deﬁning
characteristic feature of malignant cells and high expression of the
glucose transporters were speciﬁcally identiﬁed in human breast
cancer cells [61–66]. Over-expression of GLUT-1 was found to be a
characteristic feature in breast cancer biopsies, with a positive
correlation between its expression and tumor grade, extent of
proliferation and invasiveness [67–72] whereas decreased expres-
sion of GLUT-4 was seen early in the development of feline obesity
[73].
Estrogens are known to inﬂuence glucose homeostasis with
dominant effects in the liver. While the mechanisms of these effects
are unknown, estrogens have been known to stimulate glucose
transport in various target organs by altering the expression of
genes encoding proteins and enzymes involved in glucose metabo-
lism [63,67,68]. Kumagai et al. [69] examined the effects of E2 and
progesterone (P) on insulin sensitivity in Ovx rats by the
euglycaemic hyperinsulinaemic clamp technique and measure-
ments of insulin-stimulated 2-deoxy-D-glucose (2-DOG) transport
and glycogen synthesis in white and red parts of the gastrocnemius,
the extensor digitorum longus and soleus muscles and in the liver
(only glycogen synthesis). They observed that Ovx was followed byinsulin resistance and paralleled by a decreased insulin-stimulated
content of 2-DOG in muscles, an index of glucose transport.
Glycogen synthesis in muscle was also decreased, although to less
extent. E2, alone or in combination with P, restored this to values of
intact controls. Ovx led to decrease in liver glycogen synthesis,
which was restored by the treatment with E2 plus P. Thus, E2 plays
an important role in the maintenance of normal insulin sensitivity
while P alone seems to be followed by insulin resistance. E2 plus P
may be of importance for maintenance of normal glycogen synthesis
in the liver. E2 stimulated GLUT-1 expression and this effect was
inhibited by tamoxifen [65,70,71]. Cheng et al. [70] observed that E2
treatment induced two-to four fold increases in Glut3 and Glut4
mRNA levels and lesser but signiﬁcant increases in Glut3 and 4
protein levels in primate cerebral cortex. Estrogens induced
approximately 3-to 4-fold increases in mRNA and protein of GLUT-
1 in the immature rat uterus [71]. E2 and epidermal growth factor
also increased protein levels of GLUT12, a novel glucose transporter
protein located intracellularly and at the cell surface, in cultured
breast cancer cells [72].
The expression of Glut-2 is also regulated by peroxisome
proliferator activator receptor-gamma (PPAR-γ) in the liver. It has
been reported that rosiglitazone, a PPAR-γ agonist, enhanced the
GLUT-2 mRNA level in the primary cultured hepatocytes and
Alexander cells, when they were transfected with PPAR-γ/RXR-α.
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mouse GLUT-2 promoter. PPAR-γ bound to the −197–184 region of
the promoter. A steroid hormone responsive element was also
identiﬁed in the promoter of this gene [73,74]. These results suggest
that liver GLUT-2 may be a direct target of PPAR-γ ligand
contributing to glucose transport into liver in a condition when
PAPR-γ expression is increased as in type-2 diabetes or in severe
obesity. There is signal cross-talk between ERs and PPAR-γ in the
regulation of estrogen-responsive genes and peroxisome prolifera-
tor-responsive genes [75,76]. It is likely that E2 and ERs are involved
in the regulation of GLUT-2 and, perhaps, other glucose transporter
genes as well.
Barros et al. [85] investigated the inﬂuence ERα and ERβ on
regulation of GLUT-4 and caveolin-1, a structural protein associated
with GLUT-4, in mouse gastrocnemius muscle. Immunohistochemical
analysis revealed that both ERs were co-expressed in the nuclei of
most muscle cells, and that their levels were not affected by the
absence of E2 in ArKO mice. GLUT-4 expression on the muscle cell
membrane was not affected by loss of ERβ but was greatly reduced in
ERαKO mice and elevated in ArKO mice, accompanied by a parallel
reduction in Glut-4 mRNA levels in ERαKO mice. Upon treatment of
ArKO mice with the ERα agonist, 2,3-bis (4-hydroxyphenyl) propio-
nitrile (PPT), GLUT-4 expression was reduced. Caveolin-1 expression
was higher in ArKOmice and lower in ERαKO and ERβKOmice than in
WT littermates. GLUT-4 and caveolin-1 were co-localized in WT and
ArKO mice but not in ERαKO and ERβKO mice. These results reveal
that ERα is a positive regulator of GLUT-4 expression, whereas ERβ has
a suppressive role. Both ERα and ERβ are necessary for optimal
caveolin-1 expression. These results indicate that co-localization of
caveolin-1 and GLUT-4 is not an absolute requirement for muscle
glucose metabolism but reduction in GLUT-4 may contribute to the
insulin resistance observed in ERαKO mice.Fig. 2. Regulation of glycolytic enzymes by E2/ERs biochemical reactions of glycolysis and the en
and/or activity of the enzymes are indicated by arrows.4.1.2. Potential disturbance of glucose transport by EDCs
Glucose transporters could be the potential targets of estrogenic
and anti-estrogenic EDCs. Sakurai et al. reported [77] that treatment of
mouse 3T3-F442A adipocytes with BPA caused increased GLUT-4
protein levels and enhanced basal and insulin-stimulated glucose
uptake. Bogacka et al. [78] observed decreased expression of GLUT-2
mRNA and increased expression of glucokinase in the hindbrain of
obese rats. By changing the expression of glucose transporter genes,
e.g. GLUT-1, GLUT-2 and GLUT-4, estrogens and estrogenic EDCs are
able to alter glucose transport and glucose metabolism, leading to
abnormal glucose metabolism which could be associated with the
development of obesity [79].
4.2. Regulation of glycolysis by E2/ERs and potential disturbance by EDCs
4.2.1. Regulation of glycolysis by E2/ERs
Glycolysis is the biochemical pathway catalyzed by a number of
enzymes, leading to the breaking down of the imported glucose and
fructose into three-carbon molecules, pyruvate, with generation of 2
molecules of NADH and ATP (Fig. 2). The enzymes participating in
glycolysis include hexokinase (HK) (e.g. glucose kinase, GK), phos-
phoglucoisomerase (PGI), phosphofructokinase (PFK), aldolase (AD),
glyceraldehyde-3-phosphate dehydrogenase (GAPD), phosphoglyce-
rate kinase (PGK), phosphoglycerate mutase (PGM), enolase (EN) and
pyruvate kinase (PK). 6-phospho fructose-2-kinase, fructose-2,6-
bisphosphatase (PFKFB) and glucose-6-phosphatase are also involved.
PFKFB is a bifunctional enzyme responsible for maintaining the
cellular level of fructose-2, 6-bisphosphate, a powerful allosteric
activator of glycolysis. Minchenko et al. [80] observed over-expression
of PFKFB-isozyme-4 (PFKFB-4) in the human breast and colon tumors
as compared to corresponding non-malignant tissues. They have
shown that breast cancer MCF-7 cells constitutively express PFKFB-4zymes that catalyze these reactions are shown. The stimulating effects of E2 on expression
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hypoxia. Over-expression of PFKFB-4 transcript levels in breast and
colon tumors correlated with the enhanced expression of PFKFB-3,
hypoxia-inducible factor (HIF)-1, HIF-1 dependent-Glut-1 and vascu-
lar endothelial growth factor (VEGF). These data clearly demonstrates
over-expression of PFKFB-4 in the breast and colon malignant tumors.
Several studies have suggested that estrogens and ERs play a role in
the regulation of glycolysis. For instance, Furman et al. [63] observed
that estrogens induced glycolysis in MCF-7 cells, which were inhibited
by temoxifen (TAM). Kostanyan and Nazaryan [81] examined the
effect of E2 on the activities of the following glycolytic enzymes in
female rat brain: HK, PFK, AD, GAPD, PGK, PGM and PK. The activities
of HK (both soluble and membrane-bound forms), PFK and PK were
increased 4h after E2 treatment, while the others remained
unchanged. The changes in activity of these enzymes were not seen
in the presence of actinomycin D. The signiﬁcant rise in the activities
of the key glycolytic enzymes was also observed in the cell culture of
mouse neuroblastoma C1300 treated with E2. Only three of the
studied isozymes, namely, HKII, B4 and K4, for HK, PFK and PK,
respectively were found to be E2-sensitive. The results suggest that rat
brain glycolysis is regulated by E2 and is carried out in neurons due to
an induction of deﬁnite isozymes. Reiss [82] examined the effects of
the ontogeny and estrogen responsiveness of PGK, PGM, En, and PK in
rat brain and uterus. In 30-day-old rats, their brain and uterus express
the fetal isoforms CK-B, PGK-A, PGM-B, En-β and PKM-2, and the
differentiated isoforms En-α and PKM-1. The activity of glycolytic
enzymes in uterus of two-day-old rats is as in brain, while CK activity
was 3 times higher in brain. The activities of the glycolytic enzymes in
brain began to increase (3–4-fold) 10 days after birth, in a coordinated
manner. In contrast to brain, the levels of glycolytic enzymes in uterus
were highest at birth, suggesting the action of a tissue-speciﬁc
mechanism for regulation of the constitutive levels of glycolytic
isozymes. All enzymes but PGM showed an increase in total activity in
uterus in response to E2. Bogacka et al. observed [78] increased
expression of GK in the hindbrain of obese rats, suggesting that altered
expression of this protein could be related to obesity More recently,
Pastorelli et al. [83] identiﬁed, using proteomic analysis, the in vivo E2-
regulated proteins in female mice and found that EN-β and PKM-2
were E2-regulated. Yan and Vatner [84] performed proteomic analysis
to study changes in proteins in hearts of four groups of monkeys:
young males (YMs); old males (OMs) and young females (YFs) and
old females (OFs). They found decreased expression of key enzymes in
glycolysis (e.g. PK, EN-α, and triosephosphate isomerase) in OMs.
These changes in glycolytic enzymes were not observed in YMs, YFs
and OFs groups. Thus, E2 enhances the expression and activities of
several key enzymes involved in glycolysis.
4.2.2. Potential disturbance of glycolysis by EDCs
Estrogenic and anti-estrogenic EDCs have been shown to have
substantial effects on glycolysis. Kim et al. [93] tested effects of
phenolic compounds such as BPA, 4-nonylphenol (NP), 4-octylphenol
(OP) and 4-propylphenol (PP) on glucose-6-phosphate dehydrogen-
ase (G6PD) in MCF-7 cells and female immature Sprague–Dawley
(SD) rats. They observed that at the concentration higher than
1×10−8 M, BPA signiﬁcantly increased the G6PD activity in a dose-
dependent manner. NP (at concentration above 1×10−9 M) also
enhanced the G6PD activity by about 1.8 times over the control. OP
producedweaker effects on G6PD thanNP did, and showed a tendency
to increase the G6PD activity whereas PP did not affect the G6PD
activity. These results show that BPA and NP have the effect of
enhancing G6PD activities in MCF-7 cells. In an in vivo GPx assay, both
BPA and E2 signiﬁcantly increased thewet uterusweights in immature
female rats. Treatment with NP (500 mg/kg/day) signiﬁcantly
increased wet uterus weights in immature female rats. This study
implies that phenolic EDCs have weak estrogenic effects on glycolysis.
Oral contraceptives (OC) containing synthetic estrogen e.g. ethinylestradiol (EE) and progestogens (P) are known to reduce glucose
tolerance. It was reported [85] that women who used OC for periods
exceeding 10 cycles (12–36 months) showed signiﬁcantly reduced
activity of PFK, a key glycolytic enzyme, by 40% and the levels of lactate
by 42% in the erythrocytes compared to controls. These observations
in women are consistent with those made in female rats and suggest
that impaired glucose tolerance is due to reduced glycolysis through
lowering the levels of PFK synthesis by EE and P. In vivo intracellular
defects in glucose metabolism were observed in obese patients with
non-insulin-dependent diabetes mellitus, characterized by decreased
glucose uptake. Consistent with the in vivo metabolic defects,
pyruvate dehydrogenase and glycogen synthase activities were
decreased in leg muscle biopsies of obese patients [86]. It has been
reported [87,88] that the phytoestrogens, genistein and daidzein,
down regulated several glycolytic enzymes including G6Pase and
PEPCK, and played important roles in regulation of glucose home-
ostasis in type 1 diabetic mice. In these cases, EE, P, genistein and
daidzein appear to act as anti-estrogen agents.
The insulin resistance of skeletal muscle in glucose-tolerant obese
individuals is associatedwith reduced activity of oxidative enzymes and
a disproportionate increase in activity of glycolytic enzymes. Non-
insulin-dependent diabetes mellitus (NIDDM) is a disorder character-
ized by even more severe insulin resistance of skeletal muscle. Many
individuals with NIDDM are obese. Simoneau et al. [89] examined
whether decreased oxidative and increased glycolytic enzyme activities
are present inNIDDM. Percutaneous biopsy of vatus lateralismusclewas
obtained in eight lean (L) and eight obese (O) non-diabetic subjects and
in eight obeseNIDDMsubjects, whichwere assayed formarker enzymes
of the glycolytic [e.g. PFK, GAPD, HK], glycogen phosphorylase and
creatine kinase, a marker of anaerobic ATP re-synthesis and oxidative
pathways e.g. citrate synthase (CS) (Tricarboxyl acid cycle) (see section
4.3.) as well as cytochrome c oxidase (mitochondrial respiratory chain)
(see section 4.4). Activities for PFK, GAPD and HK were highest in
subjects with NIDDM, following the order of NIDDMNONL, whereas
maximum rate for CS, cytochrome c oxidase was the lowest in subjects
with NIDDM. The ratio of glycolytic/oxidative enzyme activities within
skeletalmuscle correlated negativelywith insulin sensitivity. TheHK/CS
ratio had the strongest correlationwith insulin sensitivity. An imbalance
between glycolytic andoxidative enzymecapacities is present inNIDDM
subjects and is more severe than in obese or lean glucose-tolerant
subjects. The altered ratio between glycolytic and oxidative enzyme
activities found in skeletal muscle of individuals with NIDDM suggests
that a deregulation between mitochondrial oxidative capacity and
capacity for glycolysis is an important component of the expression of
insulin resistance [89]. These observations indicate that disturbances of
glycolysis by EDCs could be related to obesity and other metabolic
diseases.
4.3. Regulation of tricarboxylic acid (TCA) cycle by E2/ERs and potential
disturbance by EDCs
4.3.1. Regulation of TCA cycle by E2/ERs
TCA cycle (also called citric acid cycle) is a biochemical pathway
(Fig. 3), which, together with MRC electron transport/oxidative
phosphorylation (see section 4.4), plays a pivotal role in cellular
respiration. TCA cycle has multiple interconnections with other
pathways and provides intermediate substrates for inter-conversion
of numerous metabolites. The enzymes and proteins involved in this
pathway are shown in Fig. 3.
Estrogens are involved in the regulation of several key enzymes in
TCA cycle. The ﬁrst reaction of TCA cycle is a condensation between
the acetyl group of acetyl-CoA and oxaloacetate to form citrate. This
reaction, a key step in TCA cycle, is catalyzed by citrate synthase (CS).
Beckett et al. [90] observed that the activity of CS in skeletal muscle of
Ovx rats treated with E2 for 16 days was signiﬁcantly higher than that
in both Ovx and Sham rats. Enhanced CS activity was also observed in
Fig. 3. Regulation of TCA cycle by estrogens/ERs. Biochemical reactions of TCA cycle and corresponding enzymes are shown (indicated by red color). Red arrows point to the enzymes
whose expression/activity are regulated by E2/ERs.
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[83] identiﬁed the enhanced expression of mitochondrial aconitase 2
in Ovx mice treated with E2, as compared with Ovx mice and Sham
mice. Yadav [92] observed that treatment Ovx female rats with E2
enhanced activities of NAD- and NADP-linked isocitrate dehydrogen-
ase (ICDH) in the brain, liver and kidney cortex. Yan and Vatner [84]
observed that the protein levels of 2-oxoglutarate dehydrogenase
were lower in left ventricular (LV) samples of old male monkeys than
those in LV samples of old female monkey, probably due to the
different E2 levels betweenmale and femalemonkeys. Gupta et al. [93]
investigated the physiological role of E2 in the regulation of energy
metabolism of epididymis of rhesus monkey. They measured the
activity of succinate dehydrogenase and malate dehydrogenase in
these two organs of (a) castrated estrogen treated and (b) castrated
estrogen+dihydrotestosterone (DHT) treated animals, and compared
with those in castrated and castrated+DHT treated animals. Their
results indicated that DHT alone stimulated the activities of all these
enzymes whereas E2 failed to stimulate any of the enzymes in
castrated animals. However, E2 in combination with DHT caused a
marked stimulation of the enzymes and the response of the
epididymis. Combination treatment was signiﬁcantly higher than
that caused by DHTalone. The results suggest that circulating estrogen
in male has a physiological role and acts synergistically with androgen
in regulating accessory sex organ function. Nilsen et al. [94]
investigated the effects of estrogens on brain mitochondrial proteome
in OVX rats using a proteomic approach. They observed that treatment
of OVX rats with E2 for 24 h signiﬁcantly enhanced the protein levels
of several enzymes involved in TCA cycle, including aconitase, PDH
E1b, PDHE2, malate dehydrogenase as well as enzymes involved in
coupling of TCA cycle with amino acid synthesis such as Glut OxaL2
and glut DH. These observations indicate that estrogens regulate the
activity and expression of enzymes involved in TCA cycle and enzymes
involved in intermediate pathways coupling with TCA cycle.
4.3.2. Potential disturbance of TCA by EDCs
There is evidence that TCA cycle is disturbed by EDCs and that this
could be related to obesity. Baltrus and Melchior [95] examined theeffects of DES on aconitase, succinate dehydrogenase and glutamic–
oxalacetic transaminase in rat pituitary and liver and observed that in
pituitary, aconitase and succinate dehydrogenase were decreased by
approximately the same amounts by DES treatment; and in liver,
succinate dehydrogenase and glutamic–oxalacetic transaminase were
decreased by DES treatment.
It has been shown that the enzymatic activities involved in TCA
cycle are reduced in obese patients. Raben et al. [96] examinedmuscle
ﬁber morphology and activities of four key enzymes, as well as energy
metabolism, in nine normal-weight post obese women and nine
matched control subjects. They observed no differences in ﬁber type
composition, but a smaller mean ﬁber area and area of ﬁber types I
and IIb were found in post obese compared with control subjects. The
activities of β-hydroxyacyl-CoA dehydrogenase (HADH) and CS were
20% lower in post obese than in control subjects. However, the
activities of lactate dehydrogenase and lipoprotein lipase were not
signiﬁcantly different between post obese and control subjects. Basal
metabolic rate and respiratory exchange ratio were similar, but
maximal oxygen uptake tended to be lower in post obese than in
control subjects. These data suggest that smaller ﬁber areas and lower
enzyme activities, i.e., markers of aerobic capacity of skeletal muscle,
may be factors predisposing to obesity.
4.4. Regulation of MRC by E2/ERs and potential disturbance by EDCs
4.4.1. Regulation of MRC by E2/ERs
Mitochondria are best known for their ability to generate the
majority (N90%) of cellular energy in the form of ATP and reactive
oxygen species (ROS) from NADH and FADH using molecular oxygen
(O2) via electron transfer/oxidative phosphorylation [97]. Mitochon-
dria also play a central role in the regulation of cellular survival and
apoptosis [98,99]. In addition, they are involved in the modulation of
important cellular processes e.g. intracellular calcium homeostasis,
various ion channels and transporters.
MRC is a major structural and functional part of mitochondria It
consists of four complexes, namely complexes I, II, III, and IV, and
mitochondrial ATP synthase (complex V) (Fig. 4). All but complex II
Fig. 4. (A) Regulation of MRC proteins by E2/ERs MRC complexes I, II, III, IV and V are shown. Genes encoded by nuclear DNA (nDNA) are indicated by green color; genes encoded by
mtDNA are indicated by blue color. The number indicates the number of protein subunits. The red, bold arrows indicate the potential effects of E2 on the expression of nDNA- and
mtDNA-genes. Potential targets for estrogenic and anti-estrogenic chemicals are marked by the block symptoms. COI, II, III: cytochrome c oxidase subunits I, II and III; cyt b:
cytochrome b; cyt c: cytochrome c; CoQ: Coenzyme Q; ND 1to ND6: NADH dehydrogenase subunits 1 to 6; mtTFA: mitochondrial transcription factor A; NRF: Nuclear respiratory
factor; PGC-1: subunits 6 and 8: ATP synthase subunits 6 and 8. (B) Role of c-myc in the regulation of MRC proteins by E2/ERs. The transcription factor, c-myc, is an E2-regulated
protein. It is involved in the stimulation of nDNA-encodedMRC gene expression. It also stimulates the expression of mtTFA, a transcription factors involved inmtDNA transcription. C-
myc coordinates the expression of both nDNA-encoded and mtDNA-encoded MRC protein synthesis, and thus enhances mitochondrial biogenesis. Red arrows indicate the
stimulating effects by E2.
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encoded by both nuclear DNA (nDNA) and mitochondrial DNA
(mtDNA). The mtDNA-encoded subunits include seven subunits of
complex I, one subunit of complex III, three subunits of complex IV and
two subunits of complex V. These mtDNA-encoded subunits carry out
the basic catalytic role of electron transport. The remaining more than
80 protein subunits are encoded by nDNA and are believed to perform
regulatory role. In addition, a number of other protein factors are
involved in replication, transcription and translation of mtDNA, all of
which are encoded by nDNA, synthesized in cytoplasm and targeted to
mitochondria. The proper MRC biogenesis depends on the coordinated
expression and correct assembly of the nDNA- and mtDNA-encoded
proteins, a complex process that requires a variety of well orchestrated
regulatory mechanisms between two separated nuclear and mitochon-
drial compartments [100,101]. A number of speciﬁc nDNA-encodedfactors are involved in the regulation of mitochondrial gene expression
and complex assembly in response to growth factors and hormone
stimuli [101]. Several lines of evidence indicate thatMRC is an important
target of estrogens and ERs. The effects of E2/ERs on MRC have been
reviewed [102]. Several important points are highlighted as follows:
4.4.1.1. Estrogens have effects on MRC structure and functions. The
effects of estrogens on mitochondrial structure [103,104], biogenesis
[105,106], respiration [107,108], and oxidative phospholylation [109–
113] have been documented. There are accumulating evidence
supporting the requirement of estrogens and ERs for the preservation
and regulation of MRC structure and function [114–124].
4.4.1.2. ERα and ERβ localize within mitochondria of E2-target cells.
ERβ is present in mitochondria of uterus, ovary [125], rat primary
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[126], the perikarya and proximal dendrites of pyramidal and granule
cells of rat coronal hippocampus [127]; human breast cancer MCF-7
[128–130], liver cancer HepG2 cells [128,129], heart cells [126]; lens
epithelial cells [131,132], osteosarcoma SaOS-2 [133] and sperm [134].
ERα is also detected in mitochondria of HepG2 [128,129], MCF-7
[128,130,135] cells and rat cerebral blood vessels [136].
4.4.1.3. Mitochondrial ERs play an important role in E2-induced mtDNA
gene expression. As indicated in Fig. 4, thirteen MRC proteins are
encoded by mtDNA. It has been shown that transcript levels of
mtDNA-genes are enhanced by estrogen in a number of cell types
including GH4C1 pituitary tumor cells [137], hippocampus from
estrogen-stimulated Ovx female rats [138], the pituitary of Ovx rats
[139], female rat liver, cultured hepatocyte and HepG2 cells [140–142],
MCF-7 cells [128], rat cerebral blood vessels [91], adipose tissue of
mice [143], human breast epithelial cells (MCF-10F) [144], and rat
brain [94]. Moreover, it was reported [145] that the levels of mtDNA-
encoded 16S RNAwere four times higher in mitochondria from female
rats than in mitochondria from male rats. In aorta of Ovx mice, the
expression of NADH-ubiquinone oxidoreductase subunit 6(ND6)
(complex I), two mitochondrial ribosomal RNAs (16S and 12S) and
three mitochondrial transfer RNAs was found to be down regulated,
principally but not exclusively due to the reduction of estrogens [146].
More importantly, the stimulating effects of E2 on mRNA levels of the
mtDNA-encoded genes were signiﬁcantly inhibited by ICI182780, a
pure ER antagonist, and by silencing the expression of ERβwith siRNA,
suggesting the involvement of ERs [135,150]. These known stimula-
tory effects of E2 on mtDNA transcription and the presence of ERs
within mitochondria of target cells indicate that mtDNA could be a
major target for E2 acting through the mitochondrial ERs.
Human mtDNA contains estrogen response elements (ERE)
(mtEREs) some of which reside in within the D-loop [147,148], a
major regulatory region for mtDNA transcription. The presence of
EREs in D-loop raises the possibility that the mitochondrial ERα and
ERβ are involved in regulation of mitochondrial gene expression via
their binding to the mtEREs. Using electrophoresis mobility shift
assays (EMSAs) and surface plasmon resonance (SPR), Chen et al.
[129] demonstrated the binding of rhERα, rhERβ and mitochondrial
extracts that contain ERβ to these mtEREs and the enhanced binding
by E2 in a dose- and time-dependent manner, indicating that the
mitochondrial ERs can interact with mtEREs and may be directly
involved in E2 induction of mtDNA transcription.
4.4.1.4. Estrogens stimulate expression of nDNA-encoded MRC proteins
and MRC activity. The majority of MRC proteins and other proteins
involved in replication, transcription and translation of mtDNA are
encoded by nDNA, synthesized in cytoplasm and targeted to
mitochondria. Proper MRC biogenesis and function depend on the
coordinated expression and correct assembly of both nDNA- and
mtDNA-encoded proteins, a complex process that requires a variety of
well orchestrated regulatory mechanisms between two physiologi-
cally separated nuclear and mitochondrial compartments [100,101].
Several studies indicate that estrogens induce the expression of
nDNA-encoded MRC proteins and stimulate mitochondrial respiration
[107,108,140,145,147,149–153]. The above observations, together with
the observed abnormal mitochondrial cristae in ARKO mice [117,154]
and in cardiocytes of ERαKO mice [115], and the gender differences in
mitochondrial morphology and functionality [118,120], suggest that E2
and ERs are involved in the coordinated expression of (i) mtDNA-
encoded subunits; (ii) nDNA-encoded subunits and (iii) nDNA-
encoded regulatory/accessory factors required for mtDNA replication,
transcription, translation and assembly. However, the molecular
mechanisms underlying these estrogen effects on expression of
nDNA-encoded MRC proteins are largely unknown and warrant
further investigation.Consistent with the observed effects of estrogens on the expression
of mtDNA- and nDNA-genes encoding MRC proteins, it has been
observed that treatmentof several types of cellswith E2 or EE stimulated
MRC activity via ERs, as reﬂected by increased generation of mitochon-
drial superoxide, ATPand increasedoxygen consumption (parameters of
MRC activity) [94,141,142,155, 156], associated with inhibition of
apoptosis and enhanced distribution of glutasthone in nucleus and
mitochondria [141,142,157,158]. It was also observed that treatment of
rats with estrogens enhanced the mitochondrial energy efﬁciency of
their cerebral blood vessels [91]. Consistent with these observation, Yan
and Vatner [84] found reduced expression and function of proteins
involved in electron transport and oxidative phosphorylation in
mitochondria only in hearts from old male monkeys, with correspond-
ing decreased oxidation rates with NADH and ascorbate-N,N,N′,N′ ″-
tetramethyl-p-phenylenediamine substrates, whereas no such changes
were observed in female monkeys. The fact that ovx-induced obesity in
mice is associated with a decrease in oxygen consumption indicates
repressed energy expenditure in the absence of E2 [159].
4.4.1.5. Regulation of nuclear-encoded MRC proteins by c-myc. Several
transcription factors including c-myc are involved in the regulation of
expression of nuclear-encoded MRC proteins. C-myc is a transcription
factor whose expression is stimulated by E2. C-myc plays a central role
in the regulation of cell size, cell proliferation and apoptosis. Gene
expression analysis suggests that over-expression of c-myc induced
nuclear-encoded MRC genes [160–162]. Li et al. [163] determined the
effects of ectopic Myc expression or the loss of Myc on mitochondrial
biogenesis. They observed that induction of c-Myc in P493-6 cells
resulted in increased oxygen consumption and mitochondrial mass
and function. Myc null rat ﬁbroblasts have diminished mitochondrial
mass and decreased number of normal mitochondria. Reconstitution
of c-myc expression in Myc null ﬁbroblasts partially restored
mitochondrial mass and function and normal-appearing mitochon-
dria. They also observed in primary hepatocytes that acute deletion of
ﬂoxed murine Myc by Cre recombinase resulted in diminished
mitochondrial mass. The microarray analysis of genes responsive to
Myc in human P493-6 B lymphocytes supports a role for Myc in
mitochondrial biogenesis, since genes involved in mitochondrial
structure and function are over-represented among the Myc-induced
genes. In addition to the known direct binding of Myc to many genes
involved in mitochondrial structure and function, Myc bound the
mitochondrial transcription factor A gene, which encodes a key
transcriptional regulator and mitochondrial DNA replication factor,
both in P493-6 lymphocytes with high ectopic MYC expression and in
serum-stimulated primary human 2091 ﬁbroblasts with induced
endogenous MYC. These observations directly established a pivotal
role for Myc in regulating mitochondrial biogenesis. The effects of c-
myc in the regulation of nuclear-encoded MRC gene expression are
mediated via ERs. Cheng et al. [164] demonstrated that c-myc
physically interacted with ERα in ERα-responsive promoters and
that estrogen enhanced the c-MYC-ERα interactions and facilitated
the association of ERα, c-MYC, and the co-activator TRRAP with these
EREs, resulting in chromatin remodeling and increased transcription.
These results suggest that ERα and c-MYC physically interact to
stabilize the ERα-co-activator complex, thereby permitting other
signal transduction pathways to ﬁne-tune estrogen-mediated signal-
ing networks. It is likely that c-myc is involved in the regulation of
nuclear-encoded MRC genes via its interaction and cooperation with
ERs because the promoters of several nuclear-encoded MRC genes
contain EREs and sp1 sites.
4.4.2. Potential disturbance of MRC by EDCs
E2/ER-mediated MRC protein synthesis and oxidative phosphor-
ylation could be disturbed by estrogenic and anti-estrogenic EDCs. As
indicated in Fig. 1, there are two potentially important targets for
EDCs: a) E2/ER-mediated nDNA-encoded MRC proteins and other
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mtDNA transcription, translation and MRC complex assembly, and b)
the E2/Mitochondrial ER-mediated mtDNA-encoded MRC proteins.
Ooe et al. [170] investigated the role of DJ-1, an activated ras-
dependent oncogene associated with the onset of familial Parkinson's
disease (PD) in humans, in oxidative stresses by BPA, which has been
reported to induce oxidative stress in rodents, to male mice and
cultured cells. They found that BPA signiﬁcantly increased the
expression level of DJ-1 in the sperm and brain in male mice. In
cultured Neuro2a and GC1 cells, BPA induced ROS production and
signiﬁcantly compromised mitochondrial function concomitant with
elevated expression and oxidization of DJ-1. DJ-1 was found to
maintain the complex I activity against BPA-induced oxidative stress
after the localization in mitochondria. These results indicate that BPA
affects MRC function and that DJ-1 plays a role in the prevention of
BPA-induced mitochondrial injury.
4.5. Regulation of adenosine nucleotide translocator (ANT) by E2/ERs
ANT mediates ATP/ADP shuttle cross mitochondrial membrane,
thereby transporting the majority of MRC-generated ATP out of
mitochondria in exchange of ADP and Pi (Fig. 5). There are several
tissue-speciﬁc isoforms of ANT, namely ANT-1, ANT-2, ANT-3 and ANT-
4. The expression of the heart-speciﬁc ANT isoform (ANT-1) is
enhanced by E2 [165]. Interestingly, the anti-apoptotic protein, Bcl-2,
is an important component of mitochondrial ANT system (Fig. 5). One
of the important functions of Bcl-2 in mitochondria is its involvement
in the regulation of ANT operation. Bcl-2 enhances ANT-dependent
ADP/ATP exchange activity by direct protein–protein interaction with
ANT [166,167]. Bcl-2 is enhanced by E2 a number of cells [142,168–
173]. In addition to regulating apoptosis, Bcl-2 and members of Bcl-2
family regulate mitochondrial and cell physiology. For instance, t-Bid,
a Bcl-2 family member, has been shown tomodulate reorganization of
mitochondrial cristae. Bcl-2 appears to regulate voltage-dependent
anion channel permeability, which has important consequences for
mitochondrial transport of adenine nucleotides, Ca2+, and other
metabolites. BAD, another member of Bcl-2 family, is required for the
binding of glucokinase to a mitochondrial complex. Thus, BAD null
mice have altered glucose homeostasis. It has been suggested that Bcl-Fig. 5. Regulation of ANT by E2/ERs Bcl-2 is an important component of ANT shuttle. The exp
stimulating effects of E2. Mitochondrial H+-ATP synthase is shown in lower panel.2 family members may regulate important mitochondrial and cellular
functions and serve as sentinels to detect abnormalities in these
pathways and, when the abnormalities are severe enough, to initiate
or facilitate cell death. Understanding these physiological processes
controlled by Bcl-2 and Bcl-2 family will not only be important in
understanding cell regulation, and may provide new insights into the
regulation of apoptosis [174] but also provide new insights into E2-
regulated ANToperation. Because Bcl-2 and t-Bid are involved in ANT-
mediated ATP/ADP shuttle and the expression of ANT-1 and Bcl-2 is
stimulated by E2, it is likely that estrogen and estrogenic chemicals are
capable of enhancing the transport of the majority of MRC-generated
ATP out of mitochondria for ATP-dependent cellular processes,
stimulating energy expenditure. On the other hand, it has been
observed [175] that an anti-estrogen, tamoxifen, decreased mitochon-
drial ANT content, inhibited the phosphate carrier and induced ATP
hydrolysis. It is possible that other EDCs with anti-estrogenic activity
are capable of similarly disturbing ANT-mediated ATP/ADP shuttle.
Further studies are required to better understand the regulation of
ANT by estrogens and anti-estrogenic EDCs.
4.6. Regulation of fatty acid β-oxidation by E2/ERs and its disturbance
by EDCs
4.6.1. Regulation of fatty acid β-oxidation by E2/ERs
Fatty acid (FA)β-oxidation is a sequence of four reactions catalyzed
by acyl-CoA dehydrogenase, enoyl-CoA hydratase, 3-L-hydroxyacyl-
CoA dehydrogenase and β-ketoacyl-CoA thiolase. The end product of
these reactions is acetyl-CoA, which can either enter TCA cycle or serve
as a precursor for FA biosynthesis (Fig. 6).
Estrogens play an important role in the regulation of β-oxidation of
fatty acids. Postmenopausal women and rodents after Ovx can become
obese. It has been reported [176] that myocardial fatty acid utilization
was higher inwomen taking estrogens when compared with men and
trended higher when compared with women not receiving E2,
suggesting that in postmenopausal women, estrogen use is associated
with increased myocardial fatty acid utilization and that estrogens are
involved in the regulation of fatty acid metabolism. Toba et al. [177]
performed biochemical analysis on the liver of ArKO mice whose
endogenous estrogen levels were undetectable. Their results revealedression of Bcl-2 and some isoforms of ANT is stimulated by E2. Red arrows indicate the
Fig. 6. Regulation of fatty acid β-oxidation by E2/ERs. The Biochemical reactions of fatty acid β-oxidation and corresponding enzymes that catalyze these reactions are shown. The
enzymes whose expression/activity are stimulated by E2/ERs are indicated by red arrow.
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fatty acid metabolism, e.g. very long fatty acyl-CoA synthase (VLACS),
medium-chain acyl-CoA dehydrogenase, and peroxisomal acyl-CoA
oxidase (AOX). The impairment was reversed to the wild-type levels
by treatment with E2. Kamei et al. [159] examined the expression
patterns of genes related to energy expenditure and lipid metabolism
in mouse tissues including adipose tissue and skeletal muscle of Ovx
mice. They found that in adipose tissue and skeletal muscle, at 2–
4 week after Ovs, levels of nuclear receptors and cofactors involved in
energy expenditure such as ERR1, PPAR-γ, PPARδ, PGC1α and PGC1β
were lower than those in control mice. The mRNA levels of their
targets, the enzymes for fatty acid β-oxidation (e.g. medium-chain
acyl-CoA dehydrogenase and acetyl-CoA oxidase) were lower. In
addition, the expression of PPAR-γ and SREBP1, transcription factors
important for lipogenesis, was decreased, as well as that of acetyl-CoA
carboxylase and fatty acid synthase, enzymes for fatty acid synthesis,
and diacyl glycerol acetyl transferase 1 and 2, enzymes for triglyceride
synthesis. These changes in gene expression are consistent with the
obese phenotype in mice after Ovx. Thus, a decrease in the expression
of energy expenditure-related genes in adipose tissue and skeletal
muscle could, in part, be responsible for obesity after Ovx. Together,
these ﬁndings indicate a pivotal role of E2 in supporting constitutive
hepatic expression of genes involved in fatty acid β-oxidation and in
maintaining lipid homeostasis [159,177,178].
4.6.2. Potential disturbance of FA β-oxidation by EDCs
A number of estrogenic and ant-estrogenic chemicals have been
shown to alter FA β-oxidation. For example, it has been reported [87]
that phytoestrogens, e.g. genistein and daidzein, prevented diabetes
onset by elevating insulin level and reducing hepatic gluconeogenic
and FA β-oxidation activity in non-obese diabetic (NOD) mice.
Adjuvant tamoxifen has been widely used for breast cancer
treatment. However, hepatic steatosis is a frequent complication
associated with adjuvant tamoxifen treatment. Impaired hepatic FA β-
oxidation in peroxisomes, microsomes, and mitochondria results in
progression of massive hepatic steatosis in estrogen deﬁciency, andthis impairment is potentially serious because about 3% of the general
population in the United States is suffering from nonalcoholic
steatohepatitis associated with obesity and hyperlipidemia. Tamox-
ifen may be involved in impairment of FA β-oxidation in liver, causing
hepatic steatosis. Equwa et al. [179] reported that impaired hepatic FA
β-oxidation in ArKO mice defective in intrinsic estrogen synthesis
could be restored by administering a statin, pitavastatin, to thesemice,
which signiﬁcantly restored expression of essential enzymes involved
in FA β-oxidation such as very long fatty acyl-CoA synthetase in
peroxisome, peroxisomal fatty acyl-CoA oxidase, and medium-chain
acyl-CoA dehydrogenase. Severe hepatic steatosis observed in ArKO
mice substantially regressed. These ﬁndings demonstrate that
pitavastatin is capable of restoring impaired FA β-oxidation in vivo
via the peroxisome proliferator-activated receptor-alpha-mediated
signaling pathway and is potent enough to ameliorate severe hepatic
steatosis in mice deﬁcient in intrinsic estrogens.
Adiponectin, which is expressed exclusively in adipose tissues, is
able to enhance FA β-oxidation via activation of AMP-activated kinase
(AMPK) and phosphorylation of acetyl-CoA carboxylase (ACC). ACC
phosphorylation and carnitine palmitoyl-transferase-1 (CPT1) activity
is rate-limiting factors in FA β-oxidation. Yun et al. [180] observed that
treatment of high-fat diet-induced obese mice with bisphenol A
diglycidyl ether (BADGE) or caffeine for 8 weeks caused a time-
depended increase in expression of adiponectin and lipid oxidative
enzymes, in association with reduced body weight and epididymal
adipose tissue weight and a marked reduction in the number of fatty
droplets in the liver.
Bitter melon (Momordica charantia) is one of the favorable
vegetables in South China. It has been shown [181–184] that feeding
diet-induced obese rats with bitter melon juice reduced adiposity,
associated with increased lipid oxidative enzyme activities, uncou-
pling protein expression, suppression of the visceral fat accumulation,
inhibition of adipocyte hypertrophy, and marked down regulation of
expressions of lipogenic genes in the adipose. The phytoestrogens
and/or other polyphenolic chemicals in bitter melon juice may be
responsible for these effects.
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tea catechins and epigallocatechin gallate (EGCG) have been demon-
strated in cell culture and animal models of obesity to reduce
adipocyte differentiation and proliferation, lipogenesis, fat mass,
body weight, fat absorption, plasma levels of triglycerides, free fatty
acids, cholesterol, glucose, insulin and leptin, as well as to increase
beta-oxidation and thermogenesis. Adipose tissue, liver, intestine, and
skeletal muscle are target organs of green tea, mediating its anti-
obesity effects. Studies conducted with human subjects report
reduced body weight and body fat, as well as increased fat oxidation
and thermogenesis and thereby conﬁrm ﬁndings in cell culture
systems and animal models of obesity [185]. It has been shown [186]
that EGCG inhibited obesity, metabolic syndrome, and fatty liver
disease in high-fat-fed mice.
Together, these observations indicate that the endogenous and
exogenous chemicals such as tamoxifen, BADGE, caffeine, phytochem-
icals in bitter melon juice and EGCG in green tea can cause altered
expression of adiponectin and lipid oxidative enzymes and correlated
with their long-term anti-obesity effects. More studies are needed to
investigate their effects on energy metabolism pathways in relation to
reduction of obesity.
5. Potential implications of disturbance of energy metabolism
pathways by EDCs in obesity
Many lines of evidence indicate that estrogens and estrogenic
chemicals are involved in the regulation of energy metabolism
pathways from glucose transport→glycolysis→TCA cycle→MRC/
Oxidative Phosphorylation→ATP translocation/usage (ANT) (Figs. 1
to 6). Thus, it is likely that the major impact of estrogens, estrogenic
and anti-estrogenic EDCs on obesity is that they inﬂuence, either
stimulate or inhibit, energy metabolism pathways by stimulating or
inhibiting the activity and/or expression of key enzymes in these
processes. Thus, they are involved in the regulation of energy balance.
Estrogens have been shown to stimulate glucose transport and
glycolysis in various target organs [63,74,75] by altering the expres-
sion levels of genes involved in glucose metabolism [65,70,71].
Estrogens also stimulate FA β-oxidation by altering hepatic expression
of FA metabolizing enzymes [177,178]. Several key enzymes in TCA
Cycle [187–189] and mitochondrial ANT [165] are enhanced by
estrogens. It is likely that E2 and ERs enhance the cellular energy
generation and expenditure by stimulating MRC function/Oxidative
phosphorylation and ANT shuttling.
The energy balance could be altered by up- or downregulation of
the expression and activity of key enzymes involved energy metabo-
lism pathways, and which, in turn, modulate the bodyweight and
obesity. For example, it was shown [48] that over-expressing the key
enzymes in glycolysis, glucokinase or 6-phospho fructose-2-kinase/
fructose-2,6-bisphosphatase, enhanced hepatic glycolysis and reduced
bodyweight and adiposity in obese mice. Over-expression of c-myc in
liver, the key transcription factors involved in the regulation of
enzymes/proteins involved in glycolysis and MRC, prevented obesity
and insulin resistance in mice [190]. Estrogens and ERs accelerate
metabolic energy expenditure ﬂow by stimulating the activity and/or
expression of key enzymes in these processes and thus, enhance
energy expenditure. E2 and ERs are important in the regulation of
energy balance. On the other hand, deﬁciency in these effects, due to
loss of estrogens in adult animals, e.g. in FSHRKOmice [191], Ovx mice
and Ovx Syrian hamster [41,143,159,192] and ARKO mice [16–18], in
postmenopausal women or due to the loss of functional ERs, e.g. in
ERKO mice and ER mutations, will lead to the inability of cells to cope
with E2-induced stimulation of these energymetabolism pathways. As
a result, the energy ﬂow will be switched from energy expenditure to
energy storage/deposition, and eventually obesity.
In general, any enzymes, particularly for those that catalyze the key
steps in energy metabolism pathways, which are regulated by E2/ERs,could be potentially important targets for estrogenic and anti-estrogenic
EDCs. Because MRC oxidative phosphorylation and ANT shuttle are the
rate-limiting pathways in overall cellular energy metabolism, distur-
bance of these pathways could lead to energy imbalance: inhibition of
these pathways will lead to the inability of cells to cope with the
continuing E2 stimulation of the upstream glucose translocation,
glycolytic and FA β-oxidation pathways, causing accumulation of
acetyl-CoA, the precursor of FA biosynthesis. As a result, the energy
ﬂow will be switched from TCA cycle→MRC→ATP production/
utilization pathways (energy expenditure) to FA biosynthesis/deposi-
tion (energy storage), and thus, obesity; On the other hand, inhibition of
other key steps in E2-induced energy expenditure pathway could block
the energy expenditure pathways, the energy ﬂow is switched toward
energy storage pathways, leading to increased triglyceride storage. Thus,
exposure to estrogenic or anti-estrogenic EDCs in critical stages of
development will disturb E2/ER-mediated MRC energy metabolism,
leading to persistent energy imbalance and ﬁnally obesity.
Increasing exposure to EDCs appears to be an emerging factor
contributing to the current obesity epidemic. To date, only a limited
number of EDCs have been used to assess the biochemical and
molecular changes at the cellular level. To determine whether
exposure to EDCs could lead to obesity and other diseases, we need
to have the reliable biomarkers for EDCs and to establish the reliable,
sensitive and accurate methods for detecting EDCs at low levels.
Currently employed laboratory tests measure the effects solely via the
classical nuclear-genomic pathways of EDCs. Because E2, EDCs and ERs
can act in nucleus, plasma membrane and mitochondria, there are
missing pathways whereby these EDCs operate. The important
pathways that could be the disturbed by EDCs are E2/ER-induced
energy metabolism pathways, particularly MRC protein synthesis and
energy metabolism. These pathways are more directly related to
obesity. As indicated in Fig. 1, there are two types of potentially
important targets for EDCs. Investigating the effects of EDCs on the
synthesis of proteins involved in glucose transport, glycolysis, TCA
cycle, MRC, ATN and FA β-oxidation could lead to identiﬁcation of
reliable biomarkers for EDCs and to develop unique, accurate, rapid,
and cost effective method for assessing the potential EDC activity
during development.
6. Conclusions and future perspectives
Evidence is accumulating that indicates that estrogens and ERs are
involved in the regulation of energy metabolism pathways from
glucose transport to glycolysis to TCA cycle to MRC/Oxidative
phosphorylation to ANT shuttle. There might be two parts of energy
expenditure: a constitutive ﬂow (Fig. 1, indicated by black arrows) and
an E2-induced ﬂow (indicated by the bold, red arrows). The key rate-
limiting steps in the energy expenditure pathways could be glucose
transport, MRC-mediated electron transport/oxidative phosphoryla-
tion and the ANT-mediated ADP/ATP shuttle. Stimulation of glucose
transport will increase the amounts of fuels for the entire energy
metabolism pathways, whereas stimulation of the last two steps of the
energy expenditure ﬂow will create a greater potential, “pulling” a
faster energy ﬂow toward ATP utilization. By stimulating of these
energy metabolism pathways, E2 and ERs enhance the cellular energy
generation and expenditure. Thus, in the absence of E2 and/or ERs, E2-
induced energy expenditure ﬂow is not operational, leading to energy
accumulation, energy imbalance and thus, obesity. On the other hand,
the E2/ER-mediated enhancement of energy metabolism pathways
could be disturbed by EDCs, leading to abnormal energy metabolism
and energy imbalance. This could be one of the important contribut-
ing factors for current increasing trend of obesity epidemic.
Further studies are needed to obtain new insights into the cellular
and molecular mechanisms underlying regulation of energy metabo-
lism pathways by estrogens and estrogenic chemicals and potential
implications in obesity that are related to increased exposure to EDCs.
1140 J.-Q. Chen et al. / Biochimica et Biophysica Acta 1793 (2009) 1128–1143Speciﬁcally, since evidence is accumulating to indicate an potential
association between perinatal exposure to endocrine-disrupting
chemicals, particular those with estrogenic or anti-estrogenic activity,
and the development of obesity later in life, further studies to address
their effects and the underlying cellular mechanisms of EDCs on
energy metabolism pathways during development stages and among
inter-generations are urgently needed. Such studies may allow
identiﬁcation of new approaches for effective prevention and/or
slowdown the trend of obesity epidemic.
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